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Table
Donor-recipient 8 HLA-allele match (N ¼ 70 units)
1 2 3 4 5 6 7 8 (N)
6/6 25% 25% 25% 25% 4
5/6 5% 19% 26% 35% 16% 43

















1 23/M MRD CR3 4.65 1 x 106 23; 75 Grade 1
GVHD
2 24/M MUD CR3 5.14 1 x 105 24; 87 Grade 1
GVHD
3 25/F MRD CR3 8.69 1 x 106 23 None
4 18/M MRD CR2 4.88 1 x 106 22; 54 None
5 18/M MUD CR4 9.45 1 x 105 24 Too early
6 6/M MUD CR3 10 1 x 105 26 Too early
Disease status: CR¼complete remission #
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very high degree of donor-recipient HLA-allele mismatch,
the low TRM and relapse rates after pediatric DCBT are
striking, with either TBI-based or chemotherapy-only con-
ditioning. Although young children could have adequate
single-unit grafts, a signiﬁcant percentage will not. There-
fore, DCBT remains an important consideration, especially
for children of ethnic minorities.
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Background: Relapse is the primary cause of treatment
failure following allogeneic HCT. Preclinical data demon-
strates that large numbers of activated NK cells can be
generated ex vivo using artiﬁcial APCs (aAPC), that these
activated NK cells readily kill pediatric leukemia, and that
activity is independent of KIR mismatch. The post-transplant
period may be favorable for expansion and survival of
adoptively transferred NK cells potentially providing an
additional anti-leukemia effect.
Methods: We initiated a Phase I trial to assess safety and
feasibility of administration of escalating doses of donor-
derived activated NK cell infusions (NK-DLI) following mye-
loablative HLA-matched T-cell depleted PBSCT. Donors
underwent apheresis for ﬁlgrastim mobilized PBSC. The
product was T cell depleted and CD34/CD56 selected. The
CD56+ fractionwas cultured for 9e11 days with a K562 based
aAPC expressing 4-1BBL and IL-15Ra plus rhIL-15 to generate
the NK-DLI. T cell add back to the CD34 selected graft ranged
from 1-2 x 10e4 T cells/kg. NK-DLI was administered at days
21 and 49 (+/- 3 days) post-transplant. Patients received a
myeloablative preparative regimen (TBI 1200 cGy and
cyclophosphamide 60 mg/kg x 2 days). Recipients of unre-
lated donor products received GVHD prophylaxis with
tacrolimus and were dose escalated separately. The starting
dose for NK-DLI was 1 x 105 NK cells/kg for unrelated donor
recipients and 1 x 106 NK cells/kg for related donor
recipients.
Results: Six patients with high-risk ALL underwent trans-
plant (Table). The median time to neutrophil and platelet
engraftment was 9 and 12 days respectively. Median whole
blood and CD3 donor chimerism at day 28 was 91% (range,
49-100%) and 52% (range, 0-97%). Despite achieving primary
engraftment, one patient had absence of donor lymphoid
engraftment and underwent a second RIC T-replete HCT to
treat secondary rejection. Another subject received DLI to
treat mixed chimerism. Although persistence or engraftmentof infused NK-DLI cannot be deﬁnitely determined, in 5 of 6
recipients, the absolute NK value post-infusionwas a median
of 2.8 fold higher (range 1.7-4.3) than the pre-infusion value.
Two subjects had grade 1 GVHD. All subjects received the
second NK infusion off any immunosuppression. With
limited follow up, all patients remain disease free (2-12
months post-HCT).
Conclusions: Infusion of ex-vivo, aAPC expanded NK-DLI is
feasible and can be safely performed followingmyeloablative
allogeneic HCT in patients with high-risk leukemia. Accrual
and follow-up are ongoing.447
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Introduction: Unrelated donor (UD) attrition is a serious
problem impacting patients awaiting a transplant. In 2011
we presented results from a study of 7541 UD showing that
donor attrition at CT was 38.2% and signiﬁcantly worse in
women, ethnic minorities, non-blood donors and those be-
ing on the register longer.
Since then 3 signiﬁcant changes have been made: the
joining age was reduced to 16-30 (previously 18-40), the
maximum BMI allowed for PBSC donors was increased from
35 to 40 and an improved tracing system for uncontactable
donors was introduced.
The objective of this work was to assess the impact of
these changes on the proportion of donors involved in the
cancellation of requests.
Methods: All CT requests made from Anthony Nolan in 2013
were reviewed, and outcomes documented. For each request,
donor characteristics were documented.
Results: In 2013, 4207 requests were performed; 56.8% were
completed, while 37.7% were cancelled for donor reasons.
The univariate analysis showed that longer duration on the
register (p<0.001), not being a blood donor (p<0.001) and
African, African-Caribbean and Asian ethnicities (p<0.001)
were associated with higher attrition rates.
Compared to our previous study we found similar attri-
tion rates overall (38.2% to 37.7%; p¼0.6). However, therewas
a reduction in donor cancellations for medical reasons (30%
to 14.8%; p < 0.001). Conversely, we found that the attrition
rates due to emigration or travel had increased (7.9% to 13%;
p<0.001).
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was seen in donors overall, the reasons were different from
our previous study. Two of the changes instituted are likely
to have contributed (lowering joining age and increasing
BMI). Further work must be done on understanding other
factors associated with attrition, and collaborating with
other international registries to permit access to donors who
have moved to other countries.448
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Disease relapse, graft vs host disease and infection remain
the major barriers to successful allogeneic stem cell trans-
plantation. We previously presented data on the use of
escalated AUC based dosing of a continuous infusion (CI) of
IV busulfan over four days (Walko, BBMT, S218, 2012). In that
report, we described use of a test dose and day 1 and 4 PK
values to determine the dose delivered, and identiﬁed dose
limiting toxicities as rash and mucositis at an AUC of
8300 um-min/day and identiﬁed an AUC MTD of approxi-
mately 6912 uM-min/day x 4 days; a 40% increase over a
standard AUC dose of 4800 uM-min/day. Here we report
additional analyses to identify patients (pts) likely to beneﬁt
from this higher dose of continuous infusion busulfan.
Methods: Patients with advanced hematologic malignancies
and adequate organ function who were appropriate for a
MUD or MRD allogeneic transplant were enrolled on an IRB
approved trial of a test dose of busulfan (.8 mg/kg x 1) fol-
lowed by escalated dose busulfan (4800-8300 uM-min/d)
given as a 90 hour continuous infusion along with ﬂudar-
abine at 30 mg/m2/d x 5. Pts received tacrolimus and either
alemtuzamab (30), ATG + MTX (19) or MTX alone (6) as GVH
prophylaxis with standard anti-infective and supportive
care.
Results: 55 pts (median age 41, range 20-55) with myeloid
(38), lymphoid (8), or biphenotypic (1) leukemias, MDS or
MF (1) or lymphomas (7) were enrolled. All 55 subjects
were analyzed according to their being in the AUC low
(group 1, 19 pts), middle (group 2, 19 pts), or high dose
(group 3, 17 pts). 17 subjects had low, 20 had intermediate,
and 18 had high-risk disease by CIBMTR criteria. For the
entire group, univariate analysis identiﬁed age, recipient
CMV status, and disease risk as signiﬁcant factors for overall
(OS) and relapse free survival (RFS). Co-morbidity scores,
GVH occurrence or prophylaxis, donor/recipient sex and
donor type (MUD or MRD) were not signiﬁcant, nor was the
non-relapse mortality rate different between the three AUCgroups. Multivariable analysis identiﬁed CMV status as
borderline signiﬁcant (p¼.07), and high vs low AUC dose
(p¼.053) and disease risk (p¼.01) as signiﬁcant for both OS
and RFS. Outcomes were similar between AUC groups 2 and
3. Differences in OS and RFS were limited to the good and
intermediate risk patients as outcomes for high-risk pa-
tients were poor for all AUC groups (0/17 RFS and 1/17 OS).
When analyzing the 38 good and intermediate risk patients,
the OS and RFS were 66% and 62.5% for combined AUC
groups 2 and 3 compared to 31% (p¼.02) for both OS and
RFS in AUC group 1.
Conclusions: Targeted, PK based, CI busulfan that is
approximately 40% higher than standard doses can result in
apparent beneﬁt for patients with CIBMTR low or interme-
diate risk disease. These doses were unable to demonstrate
beneﬁt in high-risk patients for whom other approaches
such as immunotherapy, hypomethylating agents, or small
molecule inhibitors may be needed.449
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Several risk scores have been developed for the prediction
of transplant related mortality (TRM) following allogeneic
hematopoietic stem cell transplantation (HSCT). These have
been validated; however, predictive performance is sub-
optimal. In addition to inherent uncertainty in such a
complex medical procedure, methodological factors
impeding prediction might be attributed to the statistical
methodology, number and quality of features collected, or
simply the population size. Using an in-silico approach (i.e.
iterative computerized simulations), based on machine
learning (ML) algorithms, we set to explore the factors
limiting prediction.
ML is a subﬁeld of computer science and artiﬁcial intelli-
gence that deals with the construction and study of systems
that can learn from data, rather than follow explicitly pro-
grammed instructions. Commonly applied in complex data
scenarios, such as ﬁnancial and technological settings, it may
be suitable for outcome prediction of HSCT.
Study design involved two phases. The ﬁrst, focused on
development of several ML based prediction models of day
